Although immunoregulatory therapies such as anti-PD-1 and CAR-T have made progresses in the treatment of solid tumors, the anti-PD-1/CTLA-4 therapy in HCC appears as a challenge. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.